Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study  by Yeh, Ming-Lun et al.
Kaohsiung Journal of Medical Sciences (2016) 32, 559e566Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLELamivudine switch therapy in chronic hepatitis B
patients achieving undetectable hepatitis B virus
DNA after 3 years of entecavir therapy: A
prospective, open-label, multicenter study
Ming-Lun Yeh a,b,c, Ching-I. Huang a, Ming-Yen Hsieh a,
Chung-Feng Huang a,b, Meng-Hsuan Hsieh a,b, Jee-Fu Huang a,b,*,
Chia-Yen Dai a,b, Zu-Yau Lin a,b, Shinn-Chern Chen a,b, Ming-Lung Yu a,b,
Wan-Long Chuang a,ba Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan
b Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan
c Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanReceived 17 June 2016; accepted 8 August 2016
Available online 7 October 2016KEYWORDS
Chronic hepatitis B;
Entecavir;
Lamivudine;
Relapse;
SwitchConflicts of interest: All authors d
* Corresponding author. Hepatobiliar
Kaohsiung City 807, Taiwan.
E-mail address: jf71218@gmail.com
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2016, Kaohsiu
BY-NC-ND license (http://creativecomAbstract The subsequent maintenance therapy in chronic hepatitis B (CHB) patients after
long-term viral replication suppression is still uncertain. We aim to evaluate the efficacy of la-
mivudine (LAM) maintenance therapy in CHB patients achieving undetectable hepatitis B virus
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or stopped ETV therapy in a prospective, open-label study. Another group of sex- and age-
matched patients with continuous ETV therapy for at least 4 years served as historical control
group. The primary outcome measurement of the study was relapse of HBV DNA (defined as
serum HBV DNA level  2000 IU/mL). A total of 74 patients, including 42 of LAM switch and
32 of the nonswitch group, were enrolled. There were no significant differences in demo-
graphics, except a higher proportion of patients with positive hepatitis B envelope antigen
in the nonswitch group at the initiation of ETV therapy. The LAM switch group had significantly
lower 1-year relapse rate of HBV within 1 year compared to the nonswitch group (14.3% vs.
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560 M.-L. Yeh et al.HBV, which was significantly lower than the rate in LAM switch group (p < 0.001). LAM switch
was the only factor associated with HBV DNA relapse. In conclusion, continuous long-term
potent nucleot(s)ide analogue therapy is mandatory for prevention of viral relapse in CHB pa-
tients.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Chronic hepatitis B (CHB) infection is the leading cause of
liver cirrhosis and hepatocellular carcinoma (HCC) in the
worldwide, especially in the AsiaePacific region [1,2]. From
15% to 40% of CHB patients eventually develop cirrhosis,
hepatic failure, and HCC. The development of effective
oral antivirals in the past decades have tremendously
changed the landscape. An effective long-term hepatitis B
virus (HBV) suppression leads to significant amelioration of
necro-inflammatory activity, decreased risk of hepatic
events and HCC, fibrosis regression, and improvement of
survival [3e5].
The current recommended first-line oral antivirals,
namely nucleot(s)ide analogue (NUC) therapy, for CHB pa-
tients are entecavir (ETV) and tenofovir disoproxil fumarate
[6e8]. Compared with interferon therapy, NUC therapy has
the advantages of having a potent antiviral effect, and
excellent tolerance without significant side effects. The
unique characteristics of long-term therapeutic intervention
of NUC therapy have constituted the core components of
current guidelines. Probably due to regional socioeconomic
consideration, the guidelines of AsiaePacific 2012 indicated
that NUC therapy for hepatitis B envelope antigen (HBeAg)-
positive CHB could be stopped if the patient had undergone
HBeAg seroconversion with undetectable HBV DNA measured
at two consecutive occasions at least 6 months apart.
Stopping treatment was also considered if undetectable HBV
DNA had been documented on three separate occasions
6 months apart in HBeAg-negative patients [9].
Recent studies from AsiaePacific indicate that poor
durability of the effectiveness after stopping NUC therapy
was observed in the majority of patients. In the study by
Reijnders et al. [10], over 40% and 50% of HBeAg-positive
patients experienced reversion of HBeAg and recurrent
viremia 4 years after HBeAg seroconversion, respectively.
Relapse of viremia after stopping NUC was also found in
HBeAg negative patients. Earlier study reported 1- and 3-
year relapse rates of 44% and 52% in HBeAg-negative pa-
tients after stopping lamivudine (LAM) therapy [11]. A
recent study demonstrated that higher to 45.3% of 95 pa-
tients had clinical relapse within 1-year after stopping ETV,
a more potent NUC, in HBeAg-negative CHB patients [12]. A
recent multicenter study also identified that the diminished
rate of relapse after stopping NUC was only related to >
12 months of consolidation therapy [13].
Thus, long-term therapy appears to be a must in most
CHB patients treated with NUCs. Whether a less potent but
more economic NUC could be switched in CHB patients
after long-term suppression of viral replication with thepotent first-line NUC remains to be explored. In the present
study, we aimed to evaluate the continuous efficacy of LAM
switch therapy in CHB patients who achieved undetectable
HBV DNA after 3 years of ETV therapy.Methods
The study was conducted according to the guidelines of the
Declaration of Helsinki and the principles of Good Clinical
Practice. The Ethics Committee of Kaohsiung Medical Uni-
versity Hospital, Kaohsiung, Taiwan approved the study
before it began. Written informed consent was obtained
from all the patients.
Study design
This study was a prospective, open-label, multicenter clin-
ical trial (Clinical Trial Registered: NCT02337127) examining
the efficacy of LAM switch therapy in CHB patients with
undetectable HBV DNA after 3 years of ETV therapy. CHB
patients who had received at least 3 years of ETV therapy
were screened for eligibility for this study. According to the
policy of the National Health Insurance of Taiwan, a dura-
tion of NUC therapy for 3 years is reimbursed. Therefore,
enrolled patients received either 3 years of LAM switch
therapy or stopped ETV therapy according to their own
voluntary decision after at least three consultation visits in
qualified hepatitis outpatient clinic (Figure 1).
The inclusion criteria were: patients aged  20 years; >
6 months treatment-free interval prior to initial ETV ther-
apy; positive HBeAg for at least 3 months prior to initial ETV
therapy; HBeAg negativity and undetectable serum HBV
DNA for more than 1 year prior to enrollment; serum
alanine aminotransferase (ALT) level < 1.5-fold the upper
limit of normal; and negative urine or serum pregnancy test
(for women of childbearing potential) documented within
the 24-hour period prior to the first dose of LAM. The
exclusion criteria were: coinfection with active hepatitis A,
hepatitis C, and/or human immunodeficiency virus; clinical
evidence of liver cirrhosis or HCC; history or other evidence
of a medical condition associated with chronic liver disease
other than CHB (e.g., hemochromatosis, autoimmune
hepatitis, metabolic liver disease, alcoholic liver disease,
toxin exposures); evidence of drug abuse (including exces-
sive alcohol consumption) within 1 year of study entry;
therapy with any systemic antineoplastic or immunomodu-
latory treatment < 6 months prior to the first dose of LAM;
and inability or unwillingness to provide informed consent
or abide by the requirements of the study.
Figure 1. Study design.
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of HBV DNA (defined as serum HBV DNA level  2000 IU/
mL). The secondary analysis was to assess the difference of
HBV DNA relapse rate between the LAM switch group and a
sex-, age-matched historical control group of patients who
received continuous ETV therapy for at least 4 years.
Laboratory analysis
The liver biochemistry, HBV serological markers, and HBV
DNA level were tested at enrollment and then every
3 months during therapeutic and follow-up periods. Hepa-
titis B surface antigen (HBsAg) and HBeAg were detected by
commercially available enzyme-linked immunosorbent
assay kits (Abbott Laboratories, North Chicago, IL, USA).
Serum HBsAg levels were quantified using the Architect
HBsAg QT assay (Abbott Diagnostics, Wiesbaden, Germany).
The sensitivity of the Architect assay ranged from 0.05 IU/
mL to 250 IU/mL. Samples with HBsAg level higher than
250 IU/mL were further diluted at 1:500 and 1:1000 to
obtain a reading within the range of the calibration curve.
The serum HBV DNA levels were determined using a Coba-
sAmpliPrep/CobasTaqMan HBV assay (CAP/CTM, version
2.0, Roche Diagnostics, Indianapolis, IN, USA; the dynamic
range was 20e1.7  108 IU/mL). Tyrosine-methionine-
aspartate-aspartate (YMDD; rt180M and rt204V) mutation
would be checked in patients of LAM switch group when
relapse of HBV DNA happened. YMDD mutation was deter-
mined by the Abbott HBV RUO Sequencing assay (Abbott
Molecular Inc., Des Plaines, IL, USA).
Statistical analysis
Continuous variables were expressed as the median (25th
percentile, 75th percentile). For the categorical variables,
the frequencies and percentages were estimated. The
ManneWhitney U test was used to compare continuous
variables and the Chi-square and Fisher exact tests were
used to compare categorical variables. Binary logistic
regression analysis was used to identify the independent
associated factors. All tests were two-sided and a p
value < 0.05 was considered statistically significant. All
analyses were performed using the SPSS version 17.0 sta-
tistical package (SPSS Inc., Chicago, IL, USA).Results
Demographics and comparison of baseline
characteristics
Two hundred and seven CHB patients who had been treated
with ETV for 3 years were considered eligible for this study.
Of them, 133 patients were excluded, including 13 who did
not meet the inclusion criteria, 45 who declined to partic-
ipate and 75 who decided to continue ETV. A total of 74
patients were finally enrolled and divided into LAM switch
(nZ 42) and nonswitch (nZ 32) groups. They received LAM
therapy or follow-up for at least 1 year (Figure 2). Another
48 treatment-naı¨ve patients who received ETV therapy for
> 4 years at the study sites were selected and served as
historical controls. Table 1 shows the demographics and
comparison of characteristics between the groups. There
was no significant difference in demographics between LAM
switch and nonswitch groups, except that a higher pro-
portion of patients were HBeAg positive in the nonswitch
group at the initiation of ETV therapy (21.4% vs. 46.9%,
pZ 0.03). Compared to ETV continuous group, nine (21.4%)
patients of LAM switch group had prior NUC experience and
there were no other significant differences in baseline
characteristics between the two groups.
Relapse of HBV DNA
The 1-year HBV DNA relapse rate of 42 patients in the LAM
switch group was 14.3% (6/42), which was significantly
lower than that (75.0%) of the 32 patients in the non-switch
group (p < 0.001). None of the 48 patients with continuous
ETV therapy developed HBV DNA relapse during the 4th year
of ETV therapy, which was significantly lower than LAM
switch group (p < 0.001). We further analyzed the HBV DNA
relapse rate of the patients who had achieved primary
treatment endpoint of regional guidelines (HBeAg sero-
conversion with undetectable HBV DNA measured on two
consecutive occasions at least 6 months apart for HBeAg
positive patients; > 2 years of therapy with undetectable
HBV DNA documented on three separate occasions 6 months
apart for HBeAg negative patients) within 3 years of ETV
therapy. The 1-year relapse rate was also significantly
lower in patients in the LAM switch group (5/37, 13.5%)
Figure 2. Study allocation flow chart.
Table 1 Characteristics of lamivudine switch, nonswitch, and historical control groups at initiation of entecavir (ETV) therapy
and study enrollment.a
LAM switch
nZ 42
Nonswitch
nZ 32
p LAM switch
nZ 42
ETV continuous
nZ 48
p
Study enrollment
Male sex 32 (76.2) 25 (78.1) 1.000 32 (76.2) 33 (68.8) 0.485
Age (y) 48 (40, 56) 53 (40, 57) 0.395 48 (40, 56) 48 (51, 58) 0.346
Prior NUCb 9 (21.4) 2 (6.3) 0.101 9 (21.4) 0 (0) 0.001
AST (U/L) 24 (20, 29) 26 (21, 30) 0.385 24 (20, 29) 26 (22, 36) 0.102
ALT (U/L) 23 (16, 29) 24 (19, 29) 0.210 23 (16, 29) 24 (18, 35) 0.302
Bilirubin (mg/dL) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.719 0.8 (0.6, 1.1) 0.9 (0.7, 1.1) 0.433
Cr (mg/dL) 0.9 (0.8, 1.0) 0.8 (0.7, 1.0) 0.056 0.9 (0.8, 1.0) 0.8 (0.6, 1.0) 0.140
HBsAg (IU/mL) 871 (399, 1913) 938 (408, 2589) 0.560 871 (399, 1913) 493 (98, 1312) 0.109
Initiation of entecavir therapy
AST (U/L) 139 (75, 333) 175 (76, 525) 0.260 139 (75, 333) 147 (53, 250) 0.548
ALT (U/L) 233 (113, 383) 252 (113, 1016) 0.262 233 (113, 383) 196 (70, 439) 0.189
Bilirubin (mg/dL) 1.1 (0.8, 2.2) 1.2 (0.9, 3.4) 0.567 1.1 (0.8, 2.2) 1.1 (0.8, 1.7) 0.408
Cr (mg/dL) 0.9 (0.7, 1.1) 0.8 (0.8, 1.0) 0.244 0.9 (0.7, 1.1) 0.9 (0.6, 1.1) 0.399
AFP (ng/mL) 6.4 (3.4, 10.1) 6.7 (4.2, 24.0) 0.200 6.4 (3.4, 10.1) 6.9 (4.0, 14.2) 0.212
Positive HBeAg 9 (21.4) 15 (46.9) 0.026 9 (21.4) 13 (27.1) 0.626
HBV DNA (log10 IU/mL) 6.4 (5.3, 7.7) 6.9 (5.6, 8.1) 0.386 6.4 (5.3, 7.7) 5.5 (4.7, 7.2) 0.124
HBsAg (IU/mL) 1756 (360, 7454) 2265 (1059, 9611) 0.455 1756 (360, 7454) 1539 (412, 6059) 0.832
AFP Z a fetoprotein; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; Cr Z creatinine; HBeAg Z hepatitis B
envelope antigen; LAM Z lamivudine; NUC Z nucleot(s)ide analogues.
a Continuous variables are expressed as median (25th and 75th percentile) and statistics with ManneWhitney U test; categorical
variables are expressed as n (%) and statistics with Chi-square test. For the ETV continuous group, Study enrollment means the initiation
of 4th.year of ETV therapy.
b Prior NUC with adefovir in one patient and lamivudine in others.
562 M.-L. Yeh et al.compared to the nonswitch group (18/24, 75.0%;
p < 0.001).
The further YMDD mutation detection identified that all
the HBV DNA relapse in five patients of the LAM switchgroup was related to YMDD mutation. Fortunately, viral
suppression without clinical relapse (HBV DNA > 2000 IU/
mL combined with ALT level > 2-fold the upper limit of
normal or 3-fold elevation of end-of-treatment ALT level)
Lamivudine switch therapy in CHB 563was achieved in all the patients within 6 months after add-
on adefovir therapy.
In the nonswitch group, 17 (53.1%) patients eventually
developed clinical relapse as well as virological relapse.
ETV therapy resumed upon the detection of clinical relapse
in all the patients and no morbidity or mortality developed.
Factor associated with HBV DNA relapse
The factors associated with HBV DNA relapse were further
analyzed in both groups and historical controls. In univari-
ate analysis, the nonswitch group was the only factor
associated with HBV DNA relapse within 1 year. Twenty-four
(80%) of the 30 patients with HBV DNA relapse compared
with eight (18.2%) of the 44 patients without relapse were
patients in the nonswitch group (p < 0.001; Table 2).
Multivariate analysis also showed that the nonswitch group
was the independent factor associated with HBV DNA
relapse within 1 year (odds ratio: 28.3, 95% confidence in-
terval: 6.77e118.39, p < 0.001). In the LAM switch group,
we found that none of factors was associated with HBV DNA
relapse within 1 year (Table 3). In the nonswitch group, the
univariate analysis revealed the high AST level at study
enrollment (p Z 0.031), and low AST (p Z 0.048) and ALT
(p Z 0.030) level at initiation of ETV therapy were factors
associated with HBV DNA relapse within 1 year (Table 4).
However, none of the factors was identified as an inde-
pendent factor in multivariate analysis.Table 2 Factors associated with relapse of hepatitis B virus (H
Relapse
nZ 30
Nonrelapse
nZ 44
Study enrollment
Male sex 23 (76.7) 34 (77.3)
Age (y) 53 (40, 57) 48 (40, 57)
Prior NUCb 4 (13.3) 7 (15.9)
AST (U/L) 26 (22, 30) 24 (20, 29)
ALT (U/L) 24 (19, 30) 23 (18, 28)
Bilirubin (mg/dL) 0.8 (0.7, 1.0) 0.8 (0.6, 1.1)
Cr (mg/dL) 0.8 (0.7, 0.9) 0.9 (0.8, 1.0)
HBsAg (IU/mL) 926 (530, 2683) 831 (370, 190
Initiation of entecavir therapy
AST (U/L) 129 (72, 390) 146 (82, 462)
ALT (U/L) 235 (112, 651) 236 (114, 867
Bilirubin (mg/dL) 1.1 (0.9, 2.1) 1.4 (0.9, 2.4)
Cr (mg/dL) 0.9 (0.8, 1.0) 0.9 (0.7, 1.0)
AFP (ng/mL) 7.0 (4.0, 21.3) 5.3 (3.8, 12.7
Positive HBeAg 13 (43.3) 11 (25.0)
HBV DNA (log10 IU/mL) 6.9 (5.7, 7.5) 6.6 (5.2, 7.8)
HBsAg (IU/mL) 1950 (1059, 5368) 3159 (360, 86
Non-switch 24 (80.0) 8 (18.2)
AFPZ a fetoprotein; ALTZ alanine aminotransferase; ASTZ aspart
HBeAg Z hepatitis B envelope antigen; NUC Z nucleot(s)ide analogu
a Continuous variables are expressed as median (25th and 75th pe
variables were expressed as n (%) and statistics with Chi-square and F
male vs female for sex; per year increase for age; positive vs negative
other continuous variables.
b Prior NUC with lamivudine in all the patients.Discussion
NUC therapy for CHB may be stopped after achieving pri-
mary treatment endpoint by current regional guidelines.
However, current evidence reveals that there is a high
relapse rate after stopping NUC therapy. Thus, long-term
NUC therapy has been adapted as the mainstream of
treatment strategy in the past decade. However, the eco-
nomic consideration derived from long-term therapeutic
strategy with current first-line NUCs remains to be a major
concern of the clinical setting of patients of undeveloped or
developing countries. Whether switching to a less potent
but more economic NUC after long-term viral suppression is
feasible or not has not been investigated. The present study
was the first one aiming to investigating the feasibility of
LAM switching therapy after 3 years of ETV with viral sup-
pression. Our study demonstrated that viral suppression
persisted in the majority of patients after switching to LAM.
By contrast, for patients who stopped therapy, a large
proportion experienced virological relapse and more than
half developed clinical relapse. Our results therefore pro-
vide robust evidence that continuous long-term therapy
with NUC is mandatory for prevention of relapse. Switching
to a less potent NUC may carry a risk of viral relapse. In
addition, the treatment duration of 3 years, even with
potent NUC and meeting with the current regional guide-
lines of stopping treatment, did not appear to be sufficient
for a long-term HBV DNA suppression.BV) DNA at 1 year.a
p OR 95% CI p
1.000 0.60 0.118e3.021 0.533
0.307 1.02 0.956e1.084 0.584
1.000 3.09 0.507e18.777 0.221
0.210
0.298
0.561
0.196
7) 0.445 1.00 0.998e1.002 0.661
0.646
) 0.758
0.337
0.995
) 0.388
0.131
0.635
59) 0.661
<0.001 28.31 6.768e118.390 <0.001
ate aminotransferase; CIZ confidence interval; CrZ creatinine;
es; OR Z odds ratio.
rcentile) and statistics with ManneWhitney U test; categorical
isher exact tests. In multivariate analysis, the unit of OR included
for prior NUC, HBeAg, and LAM switch; per unit increase for the
Table 3 Factors associated with relapse of hepatitis B virus (HBV) DNA at 1 year in the lamivudine switch group.a
Relapse
nZ 6
Nonrelapse
nZ 36
p
Study enrollment
Male sex 5 (83.3) 27 (75.0) >0.999
Age (y) 44 (33, 54) 48 (41, 57) 0.276
Prior NUCb 3 (50.0) 6 (16.7) 0.101
AST (U/L) 22 (19, 26) 24 (20, 30) 0.247
ALT (U/L) 16 (14, 29) 23 (18, 30) 0.184
Bilirubin (mg/dL) 0.8 (0.6, 0.9) 0.8 (0.6, 1.1) 0.481
Cr (mg/dL) 1.0 (0.9, 1.1) 0.9 (0.8, 1.1) 0.430
HBsAg level (IU/mL) 1099 (329, 3454) 811 (437, 1780) 0.495
Initiation of entecavir therapy
AST (U/L) 115 (90, 502) 141 (72, 323) 0.984
ALT (U/L) 265 (111, 705) 212 (112, 400) 0.596
Bilirubin (mg/dL) 1.0 (0.6, 1.8) 13. (0.8, 2.2) 0.276
Cr (mg/dL) 1.0 (0.9, 1.2) 0.9 (0.7, 1.0) 0.089
AFP (ng/mL) 8.4 (2.8, 11.3) 5.1 (3.3, 9.0) 0.841
Positive HBeAg 2 (33.3) 7 (19.4) 0.593
HBV DNA (log10 IU/mL) 6.3 (5.7, 7.6) 6.4 (5.0, 7.7) 0.791
HBsAg level (IU/mL) 1462 (1118, 5859) 2018 (321, 8019) 0.932
AFP Z a fetoprotein; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; Cr Z creatinine; HBeAg Z hepatitis B
envelope antigen; NUC Z nucleot(s)ide analogues.
a Continuous variables are expressed as median (25th and 75th percentile) and statistics with ManneWhitney U test; categorical
variables are expressed as n (%) and statistics with Chi-square test.
b Prior NUC with lamivudine in all the patients.
Table 4 Factors associated with relapse of hepatitis B virus (HBV) DNA at 1 year in the nonswitch group.a
Relapse
nZ 24
Nonrelapse
nZ 8
p OR 95% CI p
Study enrollment
Male sex 18 (75.0) 7 (87.5) 0.646
Age (y) 53 (44, 57) 41 (27, 56) 0.106
Prior NUCb 1 (4.2) 1 (12.5) 0.444
AST (U/L) 26 (24, 31) 21 (19, 27) 0.031 1.18 0.941e1.492 0.150
ALT (U/L) 25 (21, 31) 20 (16, 25) 0.061
Bilirubin (mg/dL) 0.8 (0.6, 1.1) 1.0 (0.7, 1.2) 0.456
Cr (mg/dL) 0.8 (0.7, 0.9) 1.0 (0.7, 1.0) 0.249
HBsAg level (IU/mL) 926 (601, 2402) 1107 (182, 7301) 0.902
Initiation of entecavir therapy
AST (U/L) 157 (71, 443) 695 (152, 1360) 0.048 1.00 0.996e1.004 0.995
ALT (U/L) 225 (111, 665) 1076 (319, 2158) 0.030 1.00 0.997e1.001 0.475
Bilirubin (mg/dL) 1.1 (0.9, 2.1) 2.4 (1.0, 3.9) 0.223
Cr (mg/dL) 0.8 (0.8, 1.0) 0.9 (0.7, 1.0) 0.603
AFP (ng/mL) 6.7 (4.1, 37.6) 7.2 (4.4, 22.5) 0.946
Positive HBeAg 11 (45.8) 4 (50.0) 1.000
HBV DNA (log10 IU/mL) 7.0 (5.6, 7.6) 6.6 (5.5, 8.3) 0.794
HBsAg level (IU/mL) 2107 (799, 5663) 7309 (2958, 42271) 0.097
AFPZ a fetoprotein; ALTZ alanine aminotransferase; ASTZ aspartate aminotransferase; CIZ confidence interval; CrZ creatinine;
HBeAg Z hepatitis B envelope antigen; NUC Z nucleot(s)ide analogues; OR Z odds ratio.
a Continuous variables are expressed as median (25th and 75th percentile) and statistics with ManneWhitney U test; categorical
variables are expressed as n (%) and statistics with Chi-square test. In multivariate analysis, the unit of OR included male vs female for
sex; per year increase for age; positive vs negative for prior NUC, HBeAg, and LAM switch; per unit increase for the other continuous
variables.
b Prior NUC with lamivudine in all the patients.
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Lamivudine switch therapy in CHB 565It has been debated whether finite NUC therapy is
feasible. Viral relapse is generally an underestimated
problem in the ultimate goal of viral eradication with cur-
rent treatment strategies. The relapse rate of the current
study was higher than previous studies [14,15]. The ETV
long-term study reveals > 95% of viral suppression and only
0.4e1.2% of mutation related virological breakthrough
[16e18]. In the present study, none of the patients
continuing ETV therapy had HBV DNA relapse and this was
the most recommended treatment, if applicable.
In the present study, we did not find any factor that was
associated with YMDD-mutation induced HBV DNA relapse.
However, high rate of YMDD mutation-related drug resis-
tance was the major limitation of LAM therapy. Several
factors including baseline high HBV DNA level, positive
HBeAg, and HBV genotype B have been reported to be
related to LAM resistance [19,20]. The reported 1-year
resistant rate of LAM was 23% and the accumulated resis-
tant rate was as high as over 50% after 3e5 years of LAM
therapy [21,22]. A relatively high rate of YMDD mutation
was still noted even when LAM was used as maintenance
therapy after viral suppression in the current study.
Age, baseline HBV DNA level, duration of consolidation,
end-of-treatment hepatitis B core antigen, and HBsAg level
have been reported as factors associated with relapse after
stopping NUC therapy [23]. A recent study reported that
HBsAg level of 2.5 log10 IU/mL at HBeAg seroconversion
predict virological relapse after stopped ETV therapy in
HBeAg-positive CHB patients [24]. In our study, high AST
level at study enrollment, and low AST and ALT level at
initiation of ETV therapy were found to be associated with
HBV DNA relapse within 1 year in univariate analysis but the
association diminished in multivariate analysis.
There were some limitations of the study. First, the
study recruited only a small number of patients. The
grouping of patients was decided by patient’s voluntary
decision. Patients may fear the efficacy and resistance of
LAM and be unwilling to participate. Secondary, this was
the first year report and whether HBV relapse accumulates
or not with longer LAM therapy was uncertain.
In conclusion, continuing ETV therapy is recommended
for CHB patients achieving viral suppression. Switching to
LAM after 3 years’ treatment with ETV raises the clinical
concern of relapse.
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